Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders
Authors
Keywords
Ipilimumab, Melanoma, Immune-related adverse events, Autoimmunity
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 67, Issue 5, Pages 825-834
Publisher
Springer Nature
Online
2018-02-27
DOI
10.1007/s00262-018-2134-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity
- (2017) Ralf Gutzmer et al. EUROPEAN JOURNAL OF CANCER
- Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials
- (2017) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of adverse events and tumor response in melanoma patients treated with tremelimumab.
- (2017) D. Pavlov et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety of the PD-1 antibody pembrolizumab in patients with high-grade adverse events under ipilimumab treatment
- (2016) C. Bender et al. ANNALS OF ONCOLOGY
- Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy
- (2016) Thomas K. Eigentler et al. CANCER TREATMENT REVIEWS
- Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
- (2016) Lisa Zimmer et al. EUROPEAN JOURNAL OF CANCER
- Prevalence Of Autoimmune Comorbidities In Patients With Metastatic Melanoma In The United States
- (2016) Q Ma et al. VALUE IN HEALTH
- Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
- (2016) Douglas B. Johnson et al. JAMA Oncology
- Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis
- (2015) Hansje-Eva Teulings et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
- (2015) Martina Sanlorenzo et al. JAMA Dermatology
- Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis
- (2015) A Doran Bostwick et al. Journal for ImmunoTherapy of Cancer
- Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease
- (2014) Magnus Pedersen et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Ipilimumab in patients with melanoma and autoimmune disease
- (2014) Chrisann Kyi et al. Journal for ImmunoTherapy of Cancer
- The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
- (2013) Caroline J. Voskens et al. PLoS One
- Final Version of 2009 AJCC Melanoma Staging and Classification
- (2009) Charles M. Balch et al. JOURNAL OF CLINICAL ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started